Blood pressure targets, medication consideration and special concerns in elderly hypertension part I: General principles and special considerations.

IF 2.6 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Heng-Yu Pan, Po-Lung Yang, Chun-Hsien Lin, Chun-Yi Chi, Chia-Wen Lu, Tai-Shuan Lai, Chih-Fan Yeh, Michael Yu-Chih Chen, Tzung-Dau Wang, Hsien-Li Kao, Yen-Hung Lin, Mu-Cyun Wang, Chih-Cheng Wu
{"title":"Blood pressure targets, medication consideration and special concerns in elderly hypertension part I: General principles and special considerations.","authors":"Heng-Yu Pan, Po-Lung Yang, Chun-Hsien Lin, Chun-Yi Chi, Chia-Wen Lu, Tai-Shuan Lai, Chih-Fan Yeh, Michael Yu-Chih Chen, Tzung-Dau Wang, Hsien-Li Kao, Yen-Hung Lin, Mu-Cyun Wang, Chih-Cheng Wu","doi":"10.1016/j.jfma.2024.09.023","DOIUrl":null,"url":null,"abstract":"<p><p>To achieve a consensus on optimal blood pressure (BP) targets for older adults remains challenging, necessitating a trade-off between cardiovascular benefits and the risk of impaired organ perfusion. Evidence suggests that age and frailty have a minimal influence on the cardiovascular benefits of intensive BP control in community-dwelling elderly. Nonetheless, an increased incidence of acute kidney injury with intensive BP control has been observed in octogenarians. Therefore, it is recommended to maintain systolic BP below 130 mmHg for hypertensive patients aged 65-80 years. If well-tolerated, a systolic BP target below 120 mmHg can be recommended for patients with chronic kidney disease (CKD). However, no conclusive evidence supports a stringent BP target for patients aged 80 years and older. The selection of antihypertensive medications for elderly patients requires consideration of their cardiovascular condition and potential contraindications. Combination therapy may be necessary to achieve the desired BP target. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are the primary choices for patients with CKD. Newer generation mineralocorticoid receptor antagonists may further reduce the risk of cardiovascular or renal events in this population. In conclusion, managing hypertension in elderly patients requires a personalized approach that balances cardiovascular benefits with potential risks, considering individual health profiles and tolerability.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Formosan Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jfma.2024.09.023","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

To achieve a consensus on optimal blood pressure (BP) targets for older adults remains challenging, necessitating a trade-off between cardiovascular benefits and the risk of impaired organ perfusion. Evidence suggests that age and frailty have a minimal influence on the cardiovascular benefits of intensive BP control in community-dwelling elderly. Nonetheless, an increased incidence of acute kidney injury with intensive BP control has been observed in octogenarians. Therefore, it is recommended to maintain systolic BP below 130 mmHg for hypertensive patients aged 65-80 years. If well-tolerated, a systolic BP target below 120 mmHg can be recommended for patients with chronic kidney disease (CKD). However, no conclusive evidence supports a stringent BP target for patients aged 80 years and older. The selection of antihypertensive medications for elderly patients requires consideration of their cardiovascular condition and potential contraindications. Combination therapy may be necessary to achieve the desired BP target. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are the primary choices for patients with CKD. Newer generation mineralocorticoid receptor antagonists may further reduce the risk of cardiovascular or renal events in this population. In conclusion, managing hypertension in elderly patients requires a personalized approach that balances cardiovascular benefits with potential risks, considering individual health profiles and tolerability.

老年高血压的血压目标、用药注意事项和特别关注事项第一部分:一般原则和特别注意事项。
要就老年人的最佳血压(BP)目标达成共识仍具有挑战性,必须在心血管获益和器官灌注受损风险之间进行权衡。有证据表明,在社区居住的老年人中,年龄和体弱对强化血压控制对心血管的益处影响很小。然而,在八旬老人中观察到,强化血压控制会增加急性肾损伤的发生率。因此,建议 65-80 岁的高血压患者将收缩压维持在 130 mmHg 以下。如果耐受性良好,可建议慢性肾脏病(CKD)患者将收缩压目标值控制在 120 mmHg 以下。然而,没有确凿证据支持为 80 岁及以上患者设定严格的血压目标值。为老年患者选择降压药物时需要考虑其心血管状况和潜在的禁忌症。要达到理想的血压目标,可能需要联合治疗。血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂是慢性肾脏病患者的主要选择。新一代矿皮质激素受体拮抗剂可进一步降低这类人群发生心血管或肾脏事件的风险。总之,老年高血压患者的管理需要采取个性化的方法,在心血管获益与潜在风险之间取得平衡,同时考虑到个人的健康状况和耐受性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.50
自引率
6.20%
发文量
381
审稿时长
57 days
期刊介绍: Journal of the Formosan Medical Association (JFMA), published continuously since 1902, is an open access international general medical journal of the Formosan Medical Association based in Taipei, Taiwan. It is indexed in Current Contents/ Clinical Medicine, Medline, ciSearch, CAB Abstracts, Embase, SIIC Data Bases, Research Alert, BIOSIS, Biological Abstracts, Scopus and ScienceDirect. As a general medical journal, research related to clinical practice and research in all fields of medicine and related disciplines are considered for publication. Article types considered include perspectives, reviews, original papers, case reports, brief communications, correspondence and letters to the editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信